Oncologist最新文献

{"title":"Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N).","authors":"Andrea T Franson, Samara L Potter, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent D Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, Donald Williams Parsons","doi":"10.1093/oncolo/oyag382","DOIUrl":"10.1093/oncolo/oyag382","url":null,"abstract":"<p><strong>Background: </strong>This is a phase II subprotocol of the National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21 years with relapsed or refractory solid tumors with RET alterations.</p><p><strong>Methods: </strong>Selpercatinib was given at 90 mg/m2/dose (maximum dose 160 mg/dose) orally twice daily for 28-day cycles until progression or intolerable toxicity. The primary aim was to determine the objective response rate, and secondary objectives included assessing the tolerability of selpercatinib and estimating the progression-free survival.</p><p><strong>Results: </strong>Two patients with papillary thyroid carcinomas harboring CCD6C-RET fusions matched to the subprotocol. One patient was deemed ineligible as they had not yet experienced tumor recurrence. The other patient enrolled and received selpercatinib at 90 mg/m2/dose, completing all 26 cycles of protocol therapy and achieving a partial response confirmed by central imaging review. There were no dose-limiting toxicities, and the patient experienced only grade 1 adverse events attributable to selpercatinib.</p><p><strong>Conclusion: </strong>There was a low match and accrual rate on this MATCH subprotocol, resulting in early termination of the study. The basis for low accrual was likely multifactorial, including the overall rarity of this genetic alteration across pediatric tumor types and accelerated FDA approval of selpercatinib in children ≥12 years old prior to the opening of this subprotocol.</p><p><strong>Clinical trial registration number: </strong>ClinicalTrials.gov (NCT04320888).</p><p><strong>Irb approved: </strong>Initial September 14, 2020.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab and cabozantinib in people with HIV and advanced solid tumors: a pilot trial and systematic review.","authors":"Haiying Cheng, Ece Cali, Mumtu Lalla, Shuai Wang, Hong Wang, Xiaonan Xue, Benjamin A Gartrell, Joseph Sparano, Lakshmi Rajdev, Melissa A Burgess, Seth Michaels Pollack, Liza C Villaruz, Missak Haigentz, Chaoyuan Kuang, Balazs Halmos","doi":"10.1093/oncolo/oyag390","DOIUrl":"10.1093/oncolo/oyag390","url":null,"abstract":"<p><strong>Background: </strong>People living with HIV (PWH) are underrepresented in immune checkpoint inhibitor (ICI) and targeted therapy trials, despite a growing burden of malignancies. Cabozantinib may remodel the tumor microenvironment by reducing immunosuppressive myeloid populations and enhancing cytotoxic T-cell infiltration, thereby augmenting antitumor immunity and providing a biologic rationale for combination with programmed cell death protein 1 (PD-1) blockade. However, prospective data on combined ICI and antiangiogenic strategies in PWH are limited.</p><p><strong>Methods: </strong>We conducted a multicenter pilot trial of cabozantinib plus nivolumab in PWH with advanced solid tumors receiving stable antiretroviral therapy. The primary endpoints were safety and feasibility. Secondary endpoints included disease control and longitudinal HIV parameters. To place the trial findings in context, we also conducted a focused systematic review of prospective studies evaluating ICIs and relevant targeted therapies in PWH with cancer.</p><p><strong>Results: </strong>Between November 2021 and January 2024, 8 participants were enrolled and 7 initiated treatment (Kaposi sarcoma, n = 5; chondrosarcoma, n = 1; prostate cancer, n = 1). No dose-limiting toxicities occurred. Grade 3 treatment-related adverse events were infrequent; no grade 4 or 5 treatment-related adverse events occurred. Among 6 response-evaluable participants, best overall response was stable disease in 5, including disease stabilization lasting >12 months in 3 heavily pretreated participants. HIV viral load and CD4 counts remained stable during treatment. The literature review supported the feasibility of immune checkpoint inhibition in selected PWH receiving antiretroviral therapy, with the strongest prospective activity signal in Kaposi sarcoma.</p><p><strong>Conclusion: </strong>Nivolumab plus cabozantinib had a manageable safety profile without an apparent loss of HIV virologic control in available measurements. Durable disease stabilization occurred in some participants, but antitumor efficacy cannot be determined from this small, heterogeneous cohort. These findings support larger dedicated studies in PWH, particularly in Kaposi sarcoma.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov identifier NCT04514484.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Reply: Immune checkpoint inhibition in medulloblastoma: moving toward biologically informed strategies.","authors":"Marta Viana-Pereira, Patrícia Fontão, Rui Manuel Reis","doi":"10.1093/oncolo/oyag387","DOIUrl":"10.1093/oncolo/oyag387","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic disclosure, end-of-life communication, and social support associated with distinct dyadic death-preparedness states among cancer dyads.","authors":"Fur-Hsing Wen, Chia-Hsun Hsieh, Wen-Chi Chou, Jen-Shi Chen, Wen-Cheng Chang, Siew Tzuh Tang","doi":"10.1093/oncolo/oyag381","DOIUrl":"10.1093/oncolo/oyag381","url":null,"abstract":"<p><strong>Background: </strong>Preparing for death is relational because patients with advanced cancer and family caregivers confront approaching death together. We examined individual and relational factors associated with distinct dyadic death-preparedness states during patients' final 6 months of life.</p><p><strong>Patients and methods: </strong>In this longitudinal cohort study of 694 patient-caregiver dyads, hierarchical generalized linear models with lagged time-varying predictors examined unprepared-concordant, cognitive-concordant, emotional-concordant, and sufficient-concordant states versus discordance across individual, relationship, and relationship-process domains.</p><p><strong>Results: </strong>Older patient age was associated with lower likelihood of cognitive concordance but higher likelihood of sufficient concordance, and higher patient educational attainment was associated with sufficient concordance. Patient- and caregiver-reported physician prognostic disclosure was associated with higher likelihoods of cognitive concordance (AORs, 3.416 and 2.411, respectively) and sufficient concordance (AORs, 3.743 and 2.854, respectively). Greater patient-reported end-of-life discussions with caregivers were associated with a higher likelihood of cognitive concordance (AOR, 1.190; 95% CI, 1.106-1.279) but a lower likelihood of emotional concordance (AOR, 0.800; 95% CI, 0.650-0.985). Higher patient- and caregiver-reported social support was associated with a lower likelihood of cognitive concordance (AORs, 0.956 and 0.945, respectively).</p><p><strong>Conclusions: </strong>Relationship-process factors were more consistently associated with dyadic death-preparedness states than individual or relationship characteristics. These findings support assessing both patients' and caregivers' cognitive and emotional preparedness and considering reported prognostic disclosure, patient-caregiver end-of-life discussions, and social-support dynamics when evaluating dyadic preparation for death.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149065823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.","authors":"Galip Can Uyar, Kadriye Başkurt, Orhun Akdoğan, Enes Yeşilbaş, Mustafa Ersoy, Tuba Uğur Tuzcu, Kadriye Bir Yücel, Mustafa Altınbaş, Ömür Berna Çakmak Öksüzoğlu, Gökşen İnanç İmamoğlu, Osman Sütcüoğlu","doi":"10.1093/oncolo/oyag396","DOIUrl":"10.1093/oncolo/oyag396","url":null,"abstract":"<p><strong>Background: </strong>Prognostic biomarkers for risk stratification remain limited in de novo metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPIs). We evaluated baseline serum 25-hydroxyvitamin D [25(OH)D] and developed and externally validated a progression-free survival (PFS) model.</p><p><strong>Methods: </strong>This multicenter retrospective study included 273 patients initiating ARPI-based therapy between January 2021 and April 2026. Etlik City Hospital formed the training cohort (n = 192; 85 PFS events), and Gazi University and Kütahya City Hospital formed the external validation cohort (n = 81; 27 PFS events). LASSO-penalized Cox regression retained age, ISUP grade group, CHAARTED disease volume, log-transformed PSA, and hemoglobin. Model B added continuous 25(OH)D. Internal validation used 1000 bootstrap resamples. Performance was assessed by the Harrell C-index, time-dependent AUC, and calibration at 1 and 2 years. PFS was the primary endpoint; overall survival analyses were exploratory. The study was not prospectively registered.</p><p><strong>Results: </strong>Higher baseline 25(OH)D was associated with longer PFS in Model B (HR per 10-ng/mL increase, 0.64; 95% CI, 0.49-0.83; P < .001). Adding 25(OH)D improved model fit (likelihood-ratio χ² = 12.71; P < .001) and increased apparent C-index from 0.712 to 0.740. In external validation, C-indices were 0.71 (95% CI, 0.64-0.78) and 0.76 (95% CI, 0.69-0.83), respectively (Δ = 0.05; 95% CI, 0.01-0.10).</p><p><strong>Conclusions: </strong>Baseline 25(OH)D added modest prognostic information beyond clinical factors, with supportive external validation. These findings do not establish treatment-predictive utility or benefit from vitamin D supplementation. Prospective validation is needed before clinical implementation.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13680101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases.","authors":"Mustafa Sefa Isin, Mehmet Berke Isler, Amor Khachemoune","doi":"10.1093/oncolo/oyag376","DOIUrl":"10.1093/oncolo/oyag376","url":null,"abstract":"<p><strong>Background: </strong>Acrokeratosis paraneoplastica (Bazex syndrome) is an obligate paraneoplastic dermatosis characterized by symmetrical acral psoriasiform lesions and nail dystrophy.</p><p><strong>Methods: </strong>We conducted a PRISMA-compliant systematic review of 99 publications (89 case reports, 10 case series) describing 106 patients to re-examine the syndrome's epidemiology, oncologic associations, clinical features, treatment response, and prognosis.</p><p><strong>Results: </strong>The mean age at onset was 63.5 years (median: 62.5 years; interquartile range [IQR]: 57-70 years); men comprised 72.6% (n = 77; 95% CI, 63.5%-80.2%), yielding a male-to-female ratio of 2.7:1. Squamous cell carcinoma accounted for 51.9% (55/106; 95% CI, 42.5%-61.2%) of associated malignancies, followed by adenocarcinomas (18.9%; 95% CI, 12.6%-27.4%) and hematologic neoplasms (8.5%; 95% CI, 4.5%-15.4%). Cutaneous lesions preceded the cancer diagnosis in 80.6% (83/103) of patients with reported chronology, with a median lead-time of 5 months (IQR 2-10 months). Nail involvement was documented in 73.6% (78/106). Following oncologic therapy, complete cutaneous clearance occurred in 36.8% (95% CI, 28.2%-46.3%) and partial improvement in 30.2% (95% CI, 22.3%-39.5%) of cases. In univariable analyses, distant metastasis (P = .021) and an aerodigestive primary site (P = .026) were nominally associated with reported mortality, although neither remained significant after multiple-comparison correction.</p><p><strong>Conclusion: </strong>Bazex syndrome should be suspected in patients presenting with treatment-resistant acral psoriasiform lesions and nail dystrophy, prompting rigorous malignancy screening.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of ASCO 2026.","authors":"Brandon A DaSilva, Alfred I Neugut, Tito Fojo, Susan E Bates","doi":"10.1093/oncolo/oyag354","DOIUrl":"10.1093/oncolo/oyag354","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers.","authors":"Merlijn U J E Graus, Thijmen H T Broekman, Sietske van Nassau, Nicol Pepels-Aarts, Geert A Cirkel, Marcel den Dulk, Brigitte C M Haberkorn, Irene E G van Hellemond, Karlijn E P E Hermans, Marjolein Y V Homs, Maartje Los, Saskia A C Luelmo, Sasja F Mulder, Mirte M Streppel, Miriam L Wumkes, Johanna W Wilmink, Ignace H J T de Hingh, Liselot B J Valkenburg-van Iersel, Judith de Vos-Geelen","doi":"10.1093/oncolo/oyag373","DOIUrl":"10.1093/oncolo/oyag373","url":null,"abstract":"<p><strong>Background: </strong>Treatment decisions in metastatic pancreatic adenocarcinoma (mPAC) involve complex tradeoffs between survival benefits and treatment burden. Shared decision-making (SDM) is crucial but challenging in emotionally charged and time-pressured consultations. This study evaluated the real-world implementation of a decision aid to support SDM in treatment decisions in mPAC care.</p><p><strong>Materials and methods: </strong>In this prospective, multicenter study across 10 Dutch expert centers, patients with mPAC and their clinicians used a newly-developed decision aid during consultations for treatment decisions. Data were collected on preferences, decision aid use, and final treatment choices, supplemented by surveys and interviews assessing feasibility and experiences. Outcomes included decision aid use, user experience, and concordance of final treatment decision with physician and patient preferences.</p><p><strong>Results: </strong>A total of 68 clinicians participated and 227 patients were counseled using the decision aid, of whom 181 patients consented to participate in the implementation study, and 135 patients used the online decision aid. Patients who received consideration time were more likely to use the decision aid (P < 0.01). Both patients and clinicians rated the decision aid positively (median score 8/10). Discordance between physician and patient preferences regarding treatment decisions was observed in 37%.</p><p><strong>Conclusion: </strong>A structured decision aid can be successfully implemented in real-world mPAC care and was highly valued by both patients and clinicians. Differences between clinician preference, patient preference, and ultimate treatment decision were frequently observed, highlighting the need to consider treatment decision-making as an ongoing process that allows time for reflection and dialogue.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New prognosis indexes specific to Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma combining functional hepatic reserve and tumor burden.","authors":"Koji Fujita, Rie Yano, Mai Nakahara, Kyoko Oura, Hironobu Suto, Asahiro Morishita, Takashi Himoto, Keiichi Okano, Hideki Kobara","doi":"10.1093/oncolo/oyag392","DOIUrl":"10.1093/oncolo/oyag392","url":null,"abstract":"<p><strong>Background: </strong>Patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) hepatocellular carcinoma (HCC) are characterized by heterogeneity in functional hepatic reserve and tumor burden. Conventional prognosis indexes are not specific to this stage. This study aimed to establish novel prognosis indexes that integrated functional hepatic reserve and tumor burden in patients with BCLC-B HCC.</p><p><strong>Methods: </strong>A total of 1843 patients with BCLC-B HCC were retrospectively enrolled from 4 hospitals. The primary endpoint was overall survival. Tumor burden was quantified as the biproduct or sum of the maximum diameter and the number of tumor nodules that is referred to as mMDN and mUS. Functional hepatic reserve was described using the albumin-bilirubin (ALBI) score.</p><p><strong>Results: </strong>Multivariate analysis demonstrated that functional hepatic reserve and tumor burden were significantly associated with overall survival. Novel prognosis indexes, termed mMDN/ALBI and mUS/ALBI, were generated by dividing mMDN and mUS by the absolute value of the ALBI score. The mMDN/ALBI and mUS/ALBI models demonstrated superior prognostic stratification of overall survival compared with the ALBI and Tokyo scores, as reflected by higher log-rank trend chi-square statistics and C-index values. Time-dependent ROC and decision curve analyses further supported their superior predictive performance and clinical utility. mMDN/ALBI ≥ 8.2 indicated poor overall survival with a median survival time of 12 to 14 months whether functional hepatic reserve was preserved or not. mUS/ALBI ≥ 5.6 also suggested the median survival time of 9 to 12 months.</p><p><strong>Conclusion: </strong>The novel prognosis indexes stratified overall survival more clearly compared to the ALBI score and Tokyo score. These indexes enable more accurate prognosis prediction for patients with BCLC-B HCC.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13693367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a role for immune checkpoint inhibitors in high-risk medulloblastoma beyond the salvage setting?","authors":"Yi-Lun Wang, Chieh-Tsai Wu, Wei-Heng Kao, Tsung-Yen Chang, Tang-Her Jaing","doi":"10.1093/oncolo/oyag386","DOIUrl":"10.1093/oncolo/oyag386","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}